



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 MARCH 2011

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 3/31/2011 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 3/31/2010 RM'000	CURRENT YEAR TO DATE 3/31/2011 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 3/31/2010 RM'000
Revenue	32,984	28,796	32,984	28,796
Cost of Sales	(19,357)	(16,927)	(19,357)	(16,927)
Gross Profit	13,627	11,869	13,627	11,869
Other operating income	207	186	207	186
Distribution costs	(2,568)	(2,723)	(2,568)	(2,723)
Administration expenses	(2,843)	(1,992)	(2,843)	(1,992)
Other operating expenses	(538)	(536)	(538)	(536)
Profit from operations	7,885	6,804	7,885	6,804
Finance costs	(10)	(12)	(10)	(12)
Share of profit after tax of associated company.	-	-	-	-
Profit before taxation	7,875	6,792	7,875	6,792
Taxation	(1,951)	(1,662)	(1,951)	(1,662)
Profit after tax for the period	5,924	5,130	5,924	5,130
Other comprehensive income	-	-	-	-
Total other comprehensive income for the period	5,924	5,130	5,924	5,130
Profit attributable to:				
Shareholders of the Company	5,924	5,130	5,924	5,130
Minority interest	-	-	-	-
	5,924	5,130	5,924	5,130
Total other comprehensive income attributable to:				
Shareholders of the Company	5,924	5,130	5,924	5,130
Minority interest	-	-	-	-
	5,924	5,130	5,924	5,130
Earnings per share (sen)				
Basic (based on weighted average)	4.27	3.70	4.27	3.70
Diluted (based on weighted average)	4.27	3.70	4.27	3.70

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
 (Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2011

	AS AT END OF CURRENT PERIOD 31/3/2011 RM'000	AS AT PRECEDING FINANCIAL YEAR ENDED 31/12/2010 RM'000
ASSETS		
Property, Plant and Equipment	100,542	100,249
Total non-current assets	100,542	100,249
Inventories	35,031	34,003
Trade & Other Receivables	35,440	34,804
Related Company	702	951
Assets classified as held for sale	1,740	1,740
Cash & Cash Equivalents	26,268	24,732
Total current assets	99,181	96,230
Total Assets	199,723	196,479
EQUITY		
Share Capital	69,739	69,739
Reserves	95,632	89,708
Treasury Shares	(1,578)	(1,578)
Total Equity	163,793	157,869
LIABILITIES		
Deferred Tax Liability	3,745	3,821
Long Term Borrowings	8,332	10,416
Total non-current liabilities	12,077	14,237
Trade & Other Payables	14,215	13,509
Amount due to related company	385	1,324
Provision	850	850
Taxation	69	356
Term Loan	8,334	8,334
Total current liabilities	23,853	24,373
Total Liabilities	35,930	38,610
Total Equity & Liabilities	199,723	196,479
Net assets per share (RM)	1.17	1.13

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)



CCM DUOPHARMA BIOTECH BERHAD (524271-W)
(Incorporated in Malaysia)
UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 31 MARCH 2011

	31 March 2011	31 December 2010
	RM '000	RM '000
Cash generated from operations:	7,401	47,005
Income taxes paid	(2,312)	(6,966)
Net cash generated from operating activities	5,089	40,039
Net cash used in investing activities	(1,470)	(25,154)
Cash generated from financing activities		
Dividend paid	-	(20,476)
Drawdown of term loan	-	3,324
Repayment of term loan	(2,083)	-
Net cash (used in) / generated from financing activities	(2,083)	(17,152)
Net (decrease) / increase in cash and cash equivalents	1,536	(2,267)
Cash and cash equivalents as at 1 January	24,732	26,999
Cash and cash equivalents as at 31 December (I)	26,268	24,732

(I) Cash and cash equivalents comprise:

	<u>RM '000</u>	<u>RM '000</u>
Cash and bank balances	3,957	1,443
Fixed deposits placed with licensed financial institutions	22,311	23,289
	26,268	24,732

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2010 and the accompanying explanatory notes attached to the interim financial statements.)